Steven Altman Biography and Net Worth

Director of DexCom


Steven R. Altman joined the Dexcom Board of Directors in 2013. Up until his retirement from Qualcomm Incorporated in January 2014, Mr. Altman served as vice chairman of Qualcomm Incorporated and as a member of Qualcomm’s executive committee. In that role, Mr. Altman provided direction and guidance on key initiatives across all areas of the business, as well as on overall vision and strategy.

Mr. Altman joined Qualcomm in 1989 and was the chief architect of Qualcomm’s strategy for licensing its broad intellectual property portfolio for wireless communications, which has accelerated the growth of CDMA technology. In that role, he was responsible for structuring and negotiating Qualcomm’s license agreements, joint ventures and strategic relationships. Under Mr. Altman’s leadership, Qualcomm entered into domestic and international licensing agreements with the world's largest telecommunications and electronics companies.

Mr. Altman began his career with the San Diego law firm of Gray, Cary, Ames & Frye (which later become DLA Piper), where he specialized in intellectual property, mergers and acquisitions, securities, and general corporate matters. He joined Qualcomm in 1989 as corporate counsel with responsibility for licensing and contracts, quickly moving up through the management ranks and becoming vice president and general counsel in 1992. He became general manager of QTL when that organization was formed in 1995; and senior vice president in 1996. In 1998, Mr. Altman was named executive vice president; and president of QTL in 2000. From 2005 to 2011, Mr. Altman served as the president of Qualcomm where his leadership and contributions helped enable Qualcomm’s successful growth, evolution and expansion.

Mr. Altman graduated from Northern Arizona University in 1983 with a bachelor’s degree in political science and administration; he received his Juris Doctor from the University of San Diego School of Law in 1986. Mr. Altman served as a board member of Ubiquiti Networks, Inc. from October 2013 to December 2015.  He is also a member of the University of California at San Diego (UCSD) Health Board of Advisors, Mr. Altman also serves as a board member for privately-held companies ViaCyte Inc. and Brain Corporation. As a former board member of the Juvenile Diabetes Research Foundation (JDRF), he remains an active supporter of the JDRF and numerous other charitable causes.

What is Steven R. Altman's net worth?

The estimated net worth of Steven R. Altman is at least $6.20 million as of January 16th, 2024. Mr. Altman owns 53,132 shares of DexCom stock worth more than $6,197,316 as of June 19th. This net worth evaluation does not reflect any other assets that Mr. Altman may own. Learn More about Steven R. Altman's net worth.

How do I contact Steven R. Altman?

The corporate mailing address for Mr. Altman and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Steven R. Altman's contact information.

Has Steven R. Altman been buying or selling shares of DexCom?

Steven R. Altman has not been actively trading shares of DexCom during the last ninety days. Most recently, Steven R. Altman sold 1,568 shares of the business's stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $122.86, for a transaction totalling $192,644.48. Following the completion of the sale, the director now directly owns 53,132 shares of the company's stock, valued at $6,527,797.52. Learn More on Steven R. Altman's trading history.

Who are DexCom's active insiders?

DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.

Are insiders buying or selling shares of DexCom?

During the last twelve months, insiders at the medical device company sold shares 39 times. They sold a total of 265,317 shares worth more than $34,660,713.42. The most recent insider tranaction occured on June, 14th when Director Bridgette P Heller sold 1,000 shares worth more than $113,550.00. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.

Information on this page was last updated on 6/14/2024.

Steven R. Altman Insider Trading History at DexCom

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/16/2024Sell1,568$122.86$192,644.4853,132View SEC Filing Icon  
12/12/2023Sell3,000$120.00$360,000.0056,700View SEC Filing Icon  
11/15/2023Sell1,000$101.26$101,260.0059,700View SEC Filing Icon  
10/16/2023Sell1,000$77.58$77,580.0060,700View SEC Filing Icon  
9/15/2023Sell1,000$101.50$101,500.0061,700View SEC Filing Icon  
8/10/2020Sell2,000$435.05$870,100.00806View SEC Filing Icon  
7/10/2020Sell2,000$437.50$875,000.00806View SEC Filing Icon  
1/2/2020Sell2,500$218.33$545,825.002,676View SEC Filing Icon  
10/1/2019Sell2,500$149.17$372,925.002,676View SEC Filing Icon  
7/1/2019Sell2,500$151.62$379,050.002,676View SEC Filing Icon  
4/1/2019Sell2,500$119.60$299,000.003,449View SEC Filing Icon  
1/2/2019Sell2,500$117.04$292,600.003,449View SEC Filing Icon  
10/1/2018Sell2,500$135.65$339,125.003,449View SEC Filing Icon  
11/6/2017Buy10,000$49.61$496,100.004,353View SEC Filing Icon  
8/18/2015Sell5,000$96.69$483,450.00View SEC Filing Icon  
See Full Table

Steven R. Altman Buying and Selling Activity at DexCom

This chart shows Steven R Altman's buying and selling at DexCom by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DexCom Company Overview

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $116.64
Low: $116.13
High: $117.49

50 Day Range

MA: $126.16
Low: $113.81
High: $139.62

2 Week Range

Now: $116.64
Low: $74.75
High: $142.00

Volume

2,192,895 shs

Average Volume

2,732,992 shs

Market Capitalization

$46.39 billion

P/E Ratio

75.25

Dividend Yield

N/A

Beta

1.22